小青龙汤加味结合西医常规疗法治疗慢性阻塞性肺病急性加重临床研究

目的：评价小青龙汤加味治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)急性加重患者的临床疗效。方法将符合纳入标准的COPD急性加重患者60例按随机数字表法分为2组各30例。常规治疗组采用常规疗法治疗；联合治疗组在常规治疗组基础上服用小青龙汤加味。应用肺功能仪检测用力肺活量(forced vital capacity, FVC)、第1秒用力呼气量(forced expiratory volume in first second, FEV1)、FEV1/FVC，并检测动脉氧分压(partial pressure of arterial oxygen, PaO2)和CO2分压(partial pressure of carbon dioxide, PaCO2)。结果治疗后，联合治疗组FVC(1.94±0.26)L比(1.55±0.33)L，t＝-2.201]、 FEV1(1.34±0.24)L 比(0.99±0.25)L ， t ＝-6.004]和 PaO2(86.12±13.26)mmHg 比(80.02±12.75)mmHg，t＝-14.158]均明显高于常规治疗组(P＜0.05)。联合治疗组总有效率显著高于常规治疗组(86.7%比70.0%；χ2＝2.095，P＝0.036)。结论小青龙汤结合常规疗法可改善 COPD 急性加重期患者的症状、体征、动脉血气和肺功能，且疗效优于常规疗法。

Xiaoqinglong decoction combined with standard treatment for acute exacerbation of chronic obstructive pulmonary disease

Objective To evaluate the therapeutic effect of Xiaoqinglong decoction combined with standard treatment for acute exacerbation of chronic obstructive pulmonary disease (COPD).Methods A total of 60 patients with acute exacerbation of COPD were enrolled and randomly divided into a standard treatment group and a combined treatment group, 30 in each group. The standard treatment group received standard therapy and the combined treatment group receivedXiao Qing Long decoction combined with standard treatment. The forced vital capacity (FVC), forced expiratory volume in first second (FEV1), FEV1/FVC were detected using a pulmonary function tester. The partial pressure of arterial oxygen (PaO2), carbon dioxide (PaCO2) were evaluated.Results After the treatment, the FVC (1.94 ± 0.26 Lvs. 1.55 ± 0.33 L;t=-2.201, P<0.05), FEV1 (1.34 ± 0.24 Lvs. 0.99 ± 0.25 L;t=-6.004,P<0.05), and PaO2 (86.12 ± 13.26 mmHgvs. 80.02 ± 12.75 mmHg;t=-14.158,P<0.05) in the combined treatment group were significantly higher than those in the standard treatment group. The total effective rate in the combined treatment group was significantly higher than that in the standard treatment group (86.7%vs.70.0%;χ2=2.095,P=0.036).Conclusions Xiaoqinglong decoction combined with standard treatment can improve symptom, sign, arterial blood gas and the pulmonary function in patients with acute exacerbation of COPD, and its efficiency is superior to standard therapy alone.